WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the ...

Core Viewpoint - Aclaris Therapeutics, Inc. reported positive clinical results from its Phase 2a trial of the ITK/JAK3 inhibitor ATI-2138, confirming its tolerability and efficacy, while also validating ITK as a therapeutic target. The company has a strong cash runway expected to fund operations into the second half of 2028, allowing for continued development of its innovative therapies for immuno-inflammatory diseases [1][2]. Pipeline Developments - The company advanced the anti-TSLP monoclonal antibody Bosakitug (ATI-045) into a Phase 2 trial for atopic dermatitis (AD), with patient dosing currently underway [5]. - Dosing has been initiated in the Phase 1a/1b clinical program for the bispecific antibody ATI-052, with expectations to complete the Phase 1a portion by the end of 2025 and provide results in early 2026 [5][6]. Financial Performance - For Q2 2025, Aclaris reported a net loss of $15.4 million, compared to a net loss of $11.0 million in Q2 2024. The total revenue for Q2 2025 was $1.8 million, down from $2.8 million in Q2 2024 [8][9]. - Research and development expenses increased to $11.4 million for Q2 2025, up from $8.8 million in the same period last year, driven by costs associated with clinical development [10]. - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $180.9 million, down from $203.9 million at the end of 2024, but still sufficient to fund operations into the second half of 2028 [7][20]. Leadership Update - Aclaris appointed Roland Kolbeck, Ph.D., as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role [6].